New collaborative effort aims to cure ALK-positive lung cancer
December 6, 2024
Lung cancer is the leading cause of cancer death worldwide, with various subtypes affecting millions of people each year. Among these, ALK-positive lung cancer frequently strikes younger people who have never smoked, including those aged between 20 and 50. Upon diagnosis, 80% of individuals already have stage 4 metastatic cancer, spread beyond the lungs to other parts of the body. Despite initially effective ALK inhibitor treatments, the cancer recurs in most patients, and there are about 70,000 people living with ALK+ lung cancer in the United States.
UPDATES ANDΒ NEWS
Radical Collaboration: A Cancer Funder Seeks to Solve the Problem of Siloed Research | Inside Philanthropy
Why some family offices are becoming cancer research’s new bankrollers | Crain Currency
π‘ππΎπΊπ ππ©π³π°πΆπ¨π© π’πΊππΌπΎπ’π Tyler Jacks: βWeβve created a new operating model for collaborative cancer research. | The Cancer Letter
2025 Year in Review: Our Scientific Progress and Clinical Impact
BE PART OF THE MISSION
Stay Informed, Make an Impact
Subscribe
Be the first to hear about cutting-edge research, pioneering projects, and the latest advancements in Break Through Cancer science. Sign up to stay informed.
Give
Your contribution fuels groundbreaking research in some of the most challenging cancers. Every gift accelerates progress. For more information please contact Michaela Forand at MF@breakthroughcancer.org or 1-800-757-9881 ext 2.
